The Development of Deuterium-Containing Drugs
... cases, this modification has the potential to have a positive impact effect on safety, efficacy and/or tolerability. By starting from compounds with welldefined human pharmacological effects – such as approved drugs – deuteration potentially provides a unique, streamlined approach to creating signif ...
... cases, this modification has the potential to have a positive impact effect on safety, efficacy and/or tolerability. By starting from compounds with welldefined human pharmacological effects – such as approved drugs – deuteration potentially provides a unique, streamlined approach to creating signif ...
Alpha-Lipoic Acid Improved Polyneuropathy Symptoms
... is a disulfide compound that is a cofactor in vital energyproducing reactions in the body. It is a potent biological antioxidant and was once thought to be a vitamin for animals and humans. It is made endogenously in humans, however the details of its synthesis are not fully understood. In certain s ...
... is a disulfide compound that is a cofactor in vital energyproducing reactions in the body. It is a potent biological antioxidant and was once thought to be a vitamin for animals and humans. It is made endogenously in humans, however the details of its synthesis are not fully understood. In certain s ...
Next Generation Therapeutics for Disorders of Complement
... Hemolysis of Type III PNH Erythrocytes ...
... Hemolysis of Type III PNH Erythrocytes ...
INHIBITOR of BACTERIAL PROTEIN SYNTHESIS
... CLINICAL USES • They are important drugs for the treatment of serious infections caused by aerobic gr(-) bacteria • When used alone they are not reliably effective in the treatment of gr(+) cocci • Antibacterial synergy may occur with the combination of wall synthesis inhibitors • Streptomycintuber ...
... CLINICAL USES • They are important drugs for the treatment of serious infections caused by aerobic gr(-) bacteria • When used alone they are not reliably effective in the treatment of gr(+) cocci • Antibacterial synergy may occur with the combination of wall synthesis inhibitors • Streptomycintuber ...
Several Human Cyclin-Dependent Kinase Inhibitors, Structurally
... IC50 value reported as >10 indicates that the compound display no activity at the highest concentration tested (10 µM); -: not tested. ...
... IC50 value reported as >10 indicates that the compound display no activity at the highest concentration tested (10 µM); -: not tested. ...
Antihypertensive Agents
... - Prevents conversion of Angiotensin I to angiotensin II (vasoconstrictor) & blocks release of aldosterone. Aldosterone promotes Na retention & K excretion. Block aldosterone & Na excreted, but H2O & K retained - Used to treat HTN primarily, - but not a 1st line drug. Also used in heart failure. - S ...
... - Prevents conversion of Angiotensin I to angiotensin II (vasoconstrictor) & blocks release of aldosterone. Aldosterone promotes Na retention & K excretion. Block aldosterone & Na excreted, but H2O & K retained - Used to treat HTN primarily, - but not a 1st line drug. Also used in heart failure. - S ...
this PDF file - The Southwest Respiratory and Critical
... cases of angioedema which present to the emergency department; 11% of these patients require ICU admission. We report two patients who required emergency surgical airways secondary to angioedema related to ACE-inhibitors. Clinicians need to remember that these situations can be extremely dangerous a ...
... cases of angioedema which present to the emergency department; 11% of these patients require ICU admission. We report two patients who required emergency surgical airways secondary to angioedema related to ACE-inhibitors. Clinicians need to remember that these situations can be extremely dangerous a ...
A comparison of intervention with losartan or captopril in acute
... decrease the need for hospitalizations in patients after myocardial infarctions. It is still unclear whether these effects could also be achieved by blocking the angiotensin II ŽATII. type 1 receptor. Methods and results: We randomized 201 patients with acute myocardial infarction treated with eithe ...
... decrease the need for hospitalizations in patients after myocardial infarctions. It is still unclear whether these effects could also be achieved by blocking the angiotensin II ŽATII. type 1 receptor. Methods and results: We randomized 201 patients with acute myocardial infarction treated with eithe ...
Discovery and development of ACE inhibitors
The discovery of an orally inactive peptide from snake venom established the important role of angiotensin converting enzyme (ACE) inhibitors in regulating blood pressure. This led to the development of Captopril, the first ACE inhibitor. When the adverse effects of Captopril became apparent new derivates were designed. Then after the discovery of two active sites of ACE: N-domain and C-domain, the development of domain-specific ACE inhibitors began.